Table 1. Demographics and clinicopathological variables of neoadjuvant bladder cancer cohort.

Pt Identifier—Age—Sex	c Stage	pStage	Bladder Tumor Transurethral Resection Lymphovascular Invasion	Neoadjuvant Chemotherapy Regimen	Cockroft-Gault eGFR (ml/min/1.73 m2)
Neo1–82–M	T2N0M0	pT3aN1Mx	Present	Cisplatin + gemcitabine	72
Neo2–58–M	T2N0M0	pT2N0Mx	Absent	MVAC	99
Neo3–79–M	T4aN1M0	pT4aN2Mx	Absent	Cisplatin + gemcitabine	81
Neo4–59–M	T2N0M0	pTON0Mx	Absent	MVAC	86
Neo5–50–M	T2N0M0	pT1N0Mx	Present	MVAC	71
Neo6–49–M	T2N0N0	pT2bN0Mx	Absent	MVAC	103
Neo7–62–M	T4aN0M0	pT4N1Mx	Absent	MVAC	62
Neo8–62–M	T3N0M0	pT3aN0(0/17)Mx	Absent	Cisplatin + gemcitabine	61
Neo9–65–M	T2N0M0	pT1N0(0/11)Mx	Absent	MVAC	97
Neo10–73–M	T2N0M0	pTisN0(0/11)Mx	Absent	Cisplatin + gemcitabine	73
Neoll–71–F	T2N0M0	pT3aN0(0/9)Mx	Not determined	Cisplatin + gemcitabine	Greater than 60
Neo12–55–F	T2N0M0	pT0N0(0/22)Mx	Absent	Dose dense MVAC	52
Neo13–76–M	T2N0M0	Not applicable	Present	Cisplatin + gemcitabine	Greater than 60
Neo14–76–F	T2N0M0	pT0N0(0/10)M0	Absent	MVAC	Greater than 60
Neo15–52–F	T2N0M0	pT0N0(0/22)Mx	Absent	MVAC	Greater than 60
Neo16–69–M	T3N0M0	pT3aN0(0/9)Mx	Present	Split dose cisplatin + gemcitabine	58
Neo17–62–M	T4N0M0	pT4aN0Mx	Present	MVAC	Greater than 60
Neo18–82–M	T2N0M0	Not applicable	Absent	Cisplatin + gemcitabine	Greater than 60
Neo19–65–F	T2N0M0	Not applicable	Absent	MVAC	59
Neo20–57–M	T2N0M0	Not applicable	Absent	Cisplatin + gemcitabine	59